Premium
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia
Author(s) -
Szekeres György,
Kéri Szabolcs,
Juhász Anna,
Rimanóczy Ágnes,
Szendi István,
Czimmer Csongor,
Janka Zoltán
Publication year - 2003
Publication title -
american journal of medical genetics part b: neuropsychiatric genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.393
H-Index - 126
eISSN - 1552-485X
pISSN - 1552-4841
DOI - 10.1002/ajmg.b.20045
Subject(s) - psychology , dopamine transporter , dopamine receptor d3 , clozapine , variable number tandem repeat , wisconsin card sorting test , risperidone , schizophrenia (object oriented programming) , olanzapine , quetiapine , dopaminergic , medicine , dopamine , global assessment of functioning , genotype , oncology , psychiatry , cognition , neuroscience , genetics , biology , neuropsychology , gene
Molecular components of the dopaminergic system may play an important role in the pathophysiology of schizophrenia. In this study, we investigated the relationship of the Ser9Gly (S/G) polymorphism of the dopamine D3 receptor (DRD3) and the variable number of tandem repeats (VNTR) polymorphism of the dopamine transporter (DAT) with therapeutic response to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) and cognitive functions. No associations were found between the DRD3 and DAT polymorphisms and schizophrenia. The S/S genotype and the S allele were more frequent in the non‐responder patients (n = 28) than in the group of responders (n = 47) (cut‐off: >20‐point improvement in Global Assessment of Functioning (GAF) scale). The patients with S/S genotype completed fewer categories and had more perseverative errors in the Wisconsin Card Sorting Test (WCST) compared with the S/G patients. The S/S and S/G patients did not differ in positive and negative symptoms, GAF scores, WCST failure to maintain set, and verbal learning. No differences in symptoms or WCST measures were observed in the patients with different DAT genotypes. These results suggest that the S/S genotype of the DRD3 is associated with worse therapeutic response and more severe executive dysfunctions in patients with schizophrenia. © 2003 Wiley‐Liss, Inc.